Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing, and providing novel therapies that enhance the lives of people with immune and hematological disorders, cancers, and rare diseases. Clinical programs include an upcoming Phase 3 study of fostamatinib in autoimmune hemolytic anemia.
TAVALISSE® (fostamatinib disodium hexahydrate) was approved in 2018. Please visit www.TAVALISSE.com to see the full Prescribing Information and to learn more.
Visit Rigel at booth #26143 to learn more and support Conquer Cancer Foundation and PDSA.